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ILLUSTRATIVE CASE
A 48-year-old man comes to your offi ce 
for a routine physical. He has a 30 pack-
year smoking history. When you talk to 
him about smoking cessation, he tells you 
he’s tried to stop more than once, but he 
can’t seem to stay motivated. You fi nd no 
evidence of chronic lung disease and do 
not perform spirometry screening. (The US 
Preventive Services Task Force does not 
recommend spirometry for asymptomatic 
patients.) But could spirometry have 
therapeutic value in this case?
Smoking is the leading modifi able risk 
factor for mortality in the United States,2 
and smoking cessation is the most effec-
tive intervention. Nortriptyline, bupro-
pion, nicotine replacement agents, and 
varenicline are effective pharmacological 
treatments.3 Adding counseling to medi-
cation signifi cantly improves quit rates 
(estimated odds ratio [OR]=1.4; 95% 
confi dence interval [CI], 1.2-1.6).3 None-
theless, physicians’ efforts to help patients 
stop smoking frequently fail. 
But another option has caught—and 
held—the attention of researchers.
❚ The promise of biomarkers 
It has long been suspected that present-
ing smokers with evidence of tobacco’s 
harmful effect on their bodies—bio-
markers—might encourage them to stop. 
Biomarkers that have been tested in ran-
domized controlled trials (RCTs) include 
spirometry, exhaled carbon monoxide 
measurement, ultrasonography of carotid 
and femoral arteries, and genetic suscep-
tibility to lung cancer, as well as combi-
nations of these markers. But the results 
of most biomarker studies have been dis-
appointing. A 2005 Cochrane Database 
review found insuffi cient evidence of the 
effectiveness of these markers in boosting 
quit rates.4 
Perform spirometry on patients 
who smoke—even if they’re 
asymptomatic—and show 
them their lung age—that is, 
the average age of a nonsmoker 
with a forced expiratory volume 
at 1 second (FEV1) equal to 
theirs. Doing so can help 
patients kick the habit.1
Strength of recommendation 
B: Based on a single well-done randomized controlled trial 
(RCT).
Parkes G, Greenhalgh T, Griffi n M, Dent R. Effect 
on smoking quit rate of telling patients their lung 
age: the Step2quit randomised controlled trial. 
BMJ. 2008;336:598-600.
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Help smokers quit: 
Tell them their “lung age”
A clever twist on presenting spirometry results 
can boost smoking cessation rates
Which of the 
following—if any—
would prevent you 
from reporting lung 
age to patients who 
smoke? (Check all 
that apply.)
 ❑ Equipment cost
 ❑  Insufﬁ cient 
reimbursement
 ❑ Insufﬁ cient staff/time
 ❑  Not convinced 
of the value
 ❑  No signiﬁ cant barriers; 
I would report lung age
 ❑  Other (please comment)
 Go to www.jfponline.com 
and take our Instant Poll
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PURLs methodology
This study was selected and 
evaluated using FPIN’s Priority 
Updates from the Research 
Literature (PURL) Surveillance 
System methodology. The 
criteria and ﬁ ndings leading to 
the selection of this study as 
a PURL can be accessed at 
www.jfponline.com/purls. 
❚  Lung age, a biomarker 
that’s easily understood 
Lung age, a clever presentation of spi-
rometry results, had not been tested in 
an RCT prior to the study we summarize 
below. Defi ned in 1985, lung age refers 
to the average age of a nonsmoker with 
a forced expiratory volume at 1 second 
(FEV1) equal to that of the person being 
tested (FIGURE 1). The primary purpose 
was to make spirometry results easier 
for patients to understand, but research-
ers also envisioned it as a way to dem-
onstrate the premature lung damage suf-
fered as a consequence of smoking.5 
STUDY SUMMARY 
❚  Graphic display more 
effective than FEV1 results
This study was a well-done, multicenter 
RCT evaluating the effect on tobacco 
quit rates of informing adult smokers 
of their lung age.1 Smokers ages 35 and 
older from 5 general practices in Eng-
land were invited to participate. The 
authors excluded patients using oxygen 
and those with a history of tuberculosis, 
lung cancer, asbestosis, bronchiectasis, 
silicosis, or pneumonectomy. The study 
included 561 participants with an aver-
age of 33 pack-years of smoking, who 
underwent spirometry before being di-
vided into an intervention or a control 
group. The researchers used standard-
ized instruments to confi rm the baseline 
comparability of the 2 groups.
Subjects in both groups were given 
information about local smoking cessa-
tion clinics and strongly encouraged to 
quit. All were told that their lung func-
tion would be retested in 12 months. 
The controls received letters with 
their spirometry results presented as 
FEV1. In contrast, participants in the in-
tervention group received the results in 
the form of a computer-generated graph-
ic display of lung age (FIGURE 2), which 
was further explained by a health care 
worker. They also received a letter within 
1 month containing the same data. Par-
ticipants were evaluated for smoking 
cessation at 12 months, and those who 
reported quitting received confi rmatory 
carbon monoxide breath testing and sal-
ivary cotinine testing. Eleven percent of 
the subjects were lost to follow-up.
❚  Quit rates higher when 
patients know lung age
At 1 year, verifi ed quit rates were 13.6% 
in the intervention group and 6.4% in 
the control group (a difference of 7.2%, 
95% CI, 2.2%-12.1%; P=.005). This 
means that for every 14 smokers who are 
told their lung age and shown a graphic 
display of this biomarker, 1 additional 
smoker will quit after 1 year. 
Contrary to what might be expect-
ed, the investigators found that quitting 
did not depend on the degree of lung 
damage. Patients with both normal 
and abnormal lung age quit smoking at 
similar rates.
For every 14 
smokers who are 
told their lung 
age and shown a 
graphic display of 
this biomarker, 1 
additional smoker 
will quit
C O N T I N U E D
FIGURE 1
MEN 
Lung age = (2.87 × height [inches]) – (31.25 × observed FEV1 [liters]) – 39.375
WOMEN 
Lung age = (3.56 × height [inches]) – (40 × observed FEV1 [liters]) – 77.28
Translating FEV1 into lung age
1
Drawing a vertical line from the patient’s age (on the horizontal axis) to reach the 
solid curve representing the lung function of the “susceptible smoker” and extend-
ing the line horizontally to reach the curve with the broken lines representing “never 
smokers” graphically shows the patient’s lung age and the accelerated decline in 
lung function associated with smoking. The patient shown here is a 52-year-old 
smoker with FEV1 equivalent to a 75-year-old nonsmoker. 
Source: Parkes G et al. BMJ. 2008;336:598-600. Reproduced with permission from the 
BMJ Publishing Group. 
Lung age helps spirometry pack a bigger punch
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WHAT’S NEW
❚  Lung age resonates more 
than spirometry alone
This is the fi rst RCT demonstrating that 
informing smokers of their lung age can 
help them quit, and the fi rst well-de-
signed study to demonstrate improved 
cessation rates using a physiological 
biomarker. The research also suggests 
that successful quitting may have less to 
do with spirometry results—the level of 
severity of lung damage it shows—than 
with the way the results are presented. 
Giving patients information about their 
lung function in an easily understand-
able format, the authors observe, ap-
pears to result in higher quit rates. 
CAVEATS
❚  Young smokers 
weren’t studied
The study did not test to see if this inter-
vention would work in younger adults, 
as only those 35 years of age and older 
were enrolled. This is a single study, and 
it is possible that the fi ndings cannot be 
generalized to other groups or are due 
to unmeasured confounding factors. 
However, the intervention is unlikely to 
cause any signifi cant harm, so we see no 
risks associated with it other than the 
cost of spirometry. 
CHALLENGES TO IMPLEMENTATION
❚  Time and expense 
of spirometry
We suspect the biggest challenges to im-
plementing this recommendation in clini-
cal practice are the expense of obtaining 
a spirometer (TABLE), staff training for 
those practices without one, and the time 
needed for the intervention. The aver-
age time to perform spirometry on study 
participants was 30 minutes; a health 
care worker spent, on average, another 
15 minutes reviewing results with each 
member of the intervention group. 
Another challenge: Not all spirom-
eters calculate lung age or can create a 
graphic similar to FIGURE 2. However, 
any FEV1 measurement, whether it is 
generated by formal pulmonary function 
testing or by an inexpensive hand-held 
meter, can easily be converted to lung age 
using the formula shown in FIGURE 1. If 
desired, the same elements—the patient’s 
age, height, and gender as well as FEV1—
could also be used to create a computer-
generated graphic display. ■
The PURLs Surveillance System is supported in part by 
Grant Number UL1RR024999 from the National Center 
For Research Resources, a Clinical Translational Sci-
ence Award to the University of Chicago. The content 
is solely the responsibility of the authors and does not 
necessarily represent the offi cial views of the National 
Center For Research Resources or the National Insti-
tutes of Health. 
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Simply using 
spirometry 
to encourage 
smoking cessation 
is not sufﬁ cient 
Spirometry: equipment costs
The initial cost of a spirometer varies widely, depending on the 
sophistication of the equipment and the available options and features. 
Additional costs—for disposable mouthpieces, line fi lters, nose clips, and 
hoses, for example—are low. A sampling of reasonably priced models well 
suited for offi ce use is shown below. All of these models meet American 
Thoracic Society criteria for spirometry, and all calculate lung age.
SPIROMETER 
MANUFACTURER/MODEL PRICE SUPPLIER
Futuremed Discovery-2  $2,125 medsupplier.com
Micro Medical MicroLoop  $1,780 Miami-med.com
Micro Medical SpiroUSB  $1,580 Miami-med.com
NDD EasyOne Frontline  $1,000 medsupplier.com
SDI Diagnostics Spirolab II  $2,600 med-electronics.com
TABLE
586_JFP0908   586 8/19/08   12:44:17 PM
